Information Provided By:
Fly News Breaks for September 11, 2019
OTLK
Sep 11, 2019 | 06:52 EDT
Ladenburg Thalmann analyst Robert LeBoyer started Outlook Therapeutics with a Buy rating and $9 price target. The analyst expects the shares to be driven by the company's clinical trial progress for ONS-5010 in wet age-related macular degeneration and the other indications.